Tyson Foods
TSN
$64.11
+0.79%
Tyson Foods, Inc. is a leading protein-focused food producer operating in the Consumer Defensive sector, specifically within Agricultural Farm Products. The company's core business involves selling raw chicken, beef, and pork, alongside a portfolio of prepared foods under well-known brands like Tyson, Jimmy Dean, Hillshire Farm, Ball Park, and Sara Lee. As a dominant market leader in the U.S. protein industry, Tyson's competitive identity is defined by its massive scale and vertical integration across its chicken and beef segments, which together constitute approximately 70% of its sales. The current investor narrative is heavily focused on navigating extreme commodity price volatility and supply chain pressures, as highlighted by recent news of a historic cattle shortage driving record beef prices, which presents both a significant cost challenge and a potential multi-year pricing opportunity for its beef processing operations. This dynamic is central to the debate around the stock, balancing margin recovery prospects against the cyclical headwinds plaguing the industry.…
TSN
Tyson Foods
$64.11
Investment Opinion: Should I buy TSN Today?
Rating: Hold. The core thesis is that Tyson Foods is a cyclical turnaround story where the anticipated margin recovery is already partially priced in, creating a balanced risk/reward profile that warrants patience rather than immediate conviction.
Supporting evidence includes a forward P/E of 14.55x based on analyst estimates, which is reasonable for a stable food company but must be weighed against the current trailing P/E of 39.79x reflecting trough earnings. Revenue growth is modest at 5.06% YoY but driven by price, not volume. The robust $1.11B in TTM free cash flow and solid balance sheet (D/E 0.49) provide fundamental support, but profitability metrics like the 0.59% net margin are severely challenged. The stock trades near its 52-week high, suggesting limited near-term technical upside.
The thesis would upgrade to a Buy if gross margins sustainably recover above 8% (Q1 FY2025 level) or if the forward P/E compresses below 12x on sustained positive earnings revisions. It would downgrade to a Sell if net income turns negative or if revenue growth decelerates into negative territory, signaling a deeper cyclical downturn. Relative to its own history and the current stage of the protein cycle, the stock appears fairly valued, pricing in a moderate recovery but leaving little margin for error.
Sign up to view all
TSN 12-Month Price Forecast
The outlook for TSN is a waiting game centered on margin execution. The valuation is in a precarious middle ground: not cheap enough to be a clear value play without proof of recovery, yet not expensive if the bullish commodity narrative plays out. The strong free cash flow and solid balance sheet prevent a bearish stance, but the catastrophic decline in profitability from a year ago warrants caution. The stance would upgrade to bullish on concrete evidence of margin expansion (e.g., two consecutive quarters of gross margin >7%) and downgrade to bearish if net income turns negative or the dividend is cut. The base case of a slow, volatile recovery is most probable.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Tyson Foods's 12-month outlook, with a consensus price target around $83.34 and implied upside of +30.0% versus the current price.
Average Target
$83.34
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$51 - $83
Analyst target range
Analyst coverage for Tyson Foods appears limited, with data indicating only 2 analysts providing estimates, which suggests the stock may have less institutional research focus than larger cap peers, potentially leading to higher volatility and less efficient price discovery. The consensus sentiment, inferred from recent institutional rating actions, is cautiously optimistic with a tilt towards 'Neutral' or 'Outperform' ratings, as seen from Mizuho's 'Outperform', Barclays' 'Overweight', and BMO Capital's 'Outperform', balanced against JP Morgan's consistent 'Neutral' stance. The average revenue estimate for the period is $60.71 billion, with a wide range from a low of $57.96 billion to a high of $62.29 billion, indicating significant uncertainty around the top-line trajectory. The high end of the EPS estimate range at $6.81 likely assumes a successful margin recovery driven by favorable commodity spreads and cost management, while the low end at $6.20 may price in a more prolonged period of industry headwinds and compressed profitability. The wide spread between high and low targets underscores the high uncertainty inherent in forecasting a company at the mercy of volatile agricultural commodity cycles.
Bulls vs Bears: TSN Investment Factors
The investment debate for Tyson Foods centers on the timing and magnitude of a margin recovery from cyclical lows, pitting strong cash generation and pricing opportunities against severely compressed profitability. Currently, the bear case holds stronger near-term evidence, as the stock's elevated trailing P/E of 39.79x is entirely dependent on a swift earnings rebound that has not yet materialized in reported financials, with Q1 net margin at just 0.59%. The single most important tension is whether the historic cattle shortage and record beef prices will translate into sustained margin expansion for Tyson's beef segment, or if continued cost pressures and potential volume declines will prolong the profitability crisis. The stock's recent technical rally suggests the market is beginning to price in the bull case, but fundamentals have yet to confirm the turnaround.
Bullish
- Strong Free Cash Flow Generation: Despite depressed earnings, Tyson generated $1.11 billion in trailing twelve-month free cash flow. This robust cash generation provides a financial cushion, supports the 3.7% dividend yield, and funds necessary capital expenditures during the industry downturn.
- Significant Margin Recovery Potential: The forward P/E of 14.55x implies a substantial earnings rebound from the current trailing P/E of 39.79x, which is inflated by cyclically low profits. Analyst EPS estimates for the high case of $6.81 suggest a return to normalized profitability, driven by improved commodity spreads.
- Historic Cattle Shortage Creates Pricing Power: Recent news highlights a historic cattle shortage driving record beef prices, with ground beef hitting $6.67. This presents a multi-year opportunity for Tyson's beef processing segment, its largest by revenue, to benefit from favorable pricing dynamics as supply constraints persist.
- Solid Balance Sheet & Liquidity: The company maintains a healthy debt-to-equity ratio of 0.49 and a current ratio of 1.55. This financial stability provides resilience to navigate cyclical volatility and positions Tyson to potentially capitalize on industry consolidation opportunities.
Bearish
- Severely Compressed Profitability: Q1 FY2026 net margin collapsed to 0.59% with net income of just $85 million, down from $359 million a year ago. Gross margin compressed to 5.73% from 8.04% YoY, indicating intense and persistent cost pressures that are eroding earnings power.
- Elevated Trailing Valuation on Depressed Earnings: The trailing P/E ratio of 39.79x is near the top of its historical range and is a mathematical artifact of severely depressed earnings. This leaves the stock vulnerable to multiple compression if the anticipated earnings recovery is slower or weaker than priced in.
- Revenue Growth Driven by Price, Not Volume: The 5.06% YoY revenue growth in Q1 FY2026 is primarily a function of higher commodity prices, not underlying volume growth. This makes top-line performance highly susceptible to commodity cycle reversals and does not reflect organic business expansion.
- Chronic Underperformance vs. Market: The stock has a 1-year relative strength of -26.34, significantly underperforming the S&P 500. Its low beta of 0.434 confirms defensive, low-volatility characteristics but also suggests limited participation in broader market rallies, constraining upside.
TSN Technical Analysis
The stock is in a sustained recovery trend from its 52-week lows, having gained 24.62% over the past six months, though its 1-year performance is more muted at +4.25%. With a current price of $64.03, the stock is trading at approximately 96% of its 52-week range, positioned very near its 52-week high of $66.41, indicating strong recent momentum but also suggesting potential overextension and limited near-term upside before encountering significant technical resistance. Recent short-term momentum is positive but shows signs of deceleration; the stock is up 4.20% over the past month, which outpaces its 3-month gain of 3.84%, yet this recent strength has occurred amidst significant underperformance relative to the broader market, as evidenced by a relative strength of -26.34 over the past year. The 1-month positive trend diverges from the stock's longer-term struggle, potentially signaling a mean-reversion rally within a broader, more challenging fundamental environment rather than a decisive trend reversal. Key technical levels are clearly defined, with immediate resistance at the 52-week high of $66.41 and primary support at the 52-week low of $50.56. A decisive breakout above $66.41 would signal a resumption of the bullish recovery trend, while a breakdown below the $60 level could indicate a failure of the recent rally. The stock's beta of 0.434 indicates it is significantly less volatile than the market, which is typical for a defensive consumer staples name but also suggests muted potential for explosive moves compared to the broader index.
Beta
0.43
0.43x market volatility
Max Drawdown
-20.5%
Largest decline past year
52-Week Range
$51-$66
Price range past year
Annual Return
+6.7%
Cumulative gain past year
| Period | TSN Return | S&P 500 |
|---|---|---|
| 1m | +0.3% | +12.2% |
| 3m | -0.8% | +2.3% |
| 6m | +24.7% | +4.7% |
| 1y | +6.7% | +29.2% |
| ytd | +10.5% | +4.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TSN Fundamental Analysis
Revenue growth has been modest but positive, with the most recent Q1 FY2026 revenue of $14.31 billion representing a 5.06% year-over-year increase. However, this growth masks a severe multi-quarter profitability crisis; sequential revenue has been volatile, and the growth is primarily driven by higher commodity prices rather than volume, as seen in the segment data where Beef ($5.77B) remains the largest contributor, followed by Chicken ($4.21B). The fundamental investment case is currently less about top-line expansion and more about the potential for margin recovery from deeply depressed levels. Profitability is severely challenged, with a net income of just $85 million in the latest quarter yielding a razor-thin net margin of 0.59%. Gross margin of 5.73% in Q1 FY2026 represents a significant compression from the 8.04% reported in Q1 FY2025, highlighting intense cost pressures. While the company remains nominally profitable on a net income basis, the trajectory shows a stark decline from the $359 million net income reported a year ago, indicating the cyclical downturn's severe impact on earnings power, though the sequential improvement from a $47 million net income in the prior quarter (Q4 FY2025) suggests the nadir may have passed. The balance sheet and cash flow provide a mixed picture of financial health; the company maintains a reasonable debt-to-equity ratio of 0.49 and a solid current ratio of 1.55, indicating adequate liquidity. Trailing twelve-month free cash flow is a robust $1.11 billion, demonstrating the company's ability to generate cash even during a down cycle, which supports its dividend. However, the return on equity is anemic at 2.62%, reflecting the poor earnings environment, and the substantial free cash flow is crucial for funding capital expenditures and maintaining the dividend payout while navigating the industry downturn.
Quarterly Revenue
$14.3B
2025-12
Revenue YoY Growth
+0.05%
YoY Comparison
Gross Margin
+0.05%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TSN Overvalued?
Given that net income is positive ($85M in latest quarter), the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio is extremely elevated at 39.79x, which is not indicative of a growth stock but rather a reflection of severely depressed earnings. The forward PE of 14.55x, based on analyst estimates, implies the market expects a significant earnings recovery, with the gap between trailing and forward multiples signaling anticipated normalization of profitability from current cyclical lows. Compared to industry averages, Tyson's valuation presents a complex picture; its forward PE of 14.55x is likely at a discount to more stable food peers but may not fully account for the cyclical risks in its commodity-exposed business. The stock's Price-to-Sales ratio of 0.35 and EV-to-Sales of 0.55 are low, suggesting the market is assigning little value to its revenue base due to margin concerns, a typical characteristic during troughs in the protein cycle. Historically, the stock's own valuation context is telling; the current trailing PE of 39.79x is near the top of its recent historical range, far above the 14.33x seen in Q1 FY2025. This elevated multiple does not signal optimism but rather mathematically results from depressed denominator (earnings). Being near historical highs on a trailing PE basis indicates the market is pricing in a swift and substantial earnings recovery; failure to deliver on these implied expectations could lead to multiple compression even if earnings improve.
PE
39.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -54x~791x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are acute, centered on profitability. Net income has collapsed 76% year-over-year to $85 million, with gross margin compressing 231 basis points to 5.73%. The company's earnings are highly leveraged to commodity spreads in its beef and chicken segments, which together constitute ~70% of sales, creating concentrated exposure to volatile input costs. While free cash flow remains strong at $1.11B, the anemic return on equity of 2.62% indicates capital is currently being deployed very inefficiently, and the dividend payout ratio of 147% is unsustainable if earnings do not recover swiftly.
Market & Competitive Risks include valuation compression and sector-specific headwinds. The stock's forward P/E of 14.55x, while reasonable, is predicated on a significant earnings recovery; failure to meet these expectations could trigger a derating. As a defensive consumer staples stock with a beta of 0.43, it faces sector rotation risk away from staples if economic growth accelerates. Competitively, its prepared foods brands (18% of sales) operate in categories 'rife with competition' where Tyson lacks a massive market share lead, limiting pricing power outside of commodity segments.
Worst-Case Scenario involves a prolonged industry downturn where high cattle costs persist without commensurate pricing power, coupled with a recession that pressures consumer demand for protein. This could lead to consecutive quarters of net losses, a dividend cut given the unsustainable payout ratio, and a loss of investor confidence in the turnaround narrative. The realistic downside from the current price of $64.03 is approximately -21% to retest the 52-week low of $50.56, which aligns with the stock's maximum drawdown of -20.51% over the provided period. In an adverse scenario with multiple compression, losses could extend toward the $45-$50 range.
FAQ
The primary risk is operational: sustained margin compression from volatile commodity costs, as evidenced by the year-over-year gross margin decline from 8.04% to 5.73%. Financial risk includes the unsustainable dividend payout ratio of 147% if earnings do not recover. Competitive risks are notable in the prepared foods segment (18% of sales), where Tyson lacks a dominant market position. Macro and market risks include the stock's chronic underperformance (1-year relative strength of -26.34) and its sensitivity to the agricultural cycle, which is largely outside management's control. The severity is highest for the profitability risk, as it directly impacts valuation and dividend sustainability.
The 12-month forecast is bifurcated, with a 50% probability base case target range of $62-$68, implying modest upside from $64.03. This assumes a gradual earnings recovery toward the consensus EPS estimate of $6.59. The bull case (30% probability) targets $70-$75, requiring a swift margin rebound and EPS near the $6.81 high estimate. The bear case (20% probability) sees a drop to $50-$55 if the recovery stalls, retesting the 52-week low. The most likely scenario is the base case of slow, volatile improvement, as the company's massive scale makes a rapid V-shaped recovery less probable in a complex commodity environment.
TSN's valuation is a tale of two multiples, making it fairly valued in context. The trailing P/E of 39.79x is mathematically inflated due to severely depressed earnings and is not a useful indicator. The forward P/E of 14.55x, based on analyst estimates for an earnings rebound, is reasonable for a large-cap food producer and may even represent a discount to more stable peers. However, low price-to-sales (0.35) and EV-to-sales (0.55) ratios suggest the market assigns little value to its revenue base due to margin concerns. Overall, the stock appears fairly valued, pricing in a moderate recovery but leaving little room for disappointment.
TSN is a Hold, not a clear-cut buy at current levels. For investors seeking a cyclical turnaround with a 3.7% yield, it offers potential, but the risk/reward is balanced. The 14.55x forward P/E prices in a significant earnings recovery that has not yet been demonstrated in reported financials, with Q1 net margin at just 0.59%. The key upside catalyst is a margin rebound driven by favorable beef spreads, but the downside risk is a retest of the 52-week low near $50 if the recovery falters. It could be a good buy for patient, contrarian investors on a pullback, but aggressive growth investors should look elsewhere.
TSN is unsuitable for short-term trading due to its low beta (0.43) and exposure to slow-moving commodity cycles. It is a long-term investment for investors willing to hold through the volatility of the protein cycle, which can last multiple years. The 3.7% dividend yield supports a total return approach for income-oriented portfolios, but the turnaround thesis requires a minimum holding period of 2-3 years to allow for margin recovery to materialize fully. Given the deep cyclicality and the stock's tendency to underperform in strong bull markets, it is best viewed as a strategic, patient holding rather than a tactical trade.